Human embryonic stem cells have virtually limitless use and enormous potential for therapeutic medicine. However, the lack of common technical standards and uniform patent criteria have hampered further technological progress. For human embryonic stem cell research in the European Union (EU), the divergent regulations among member states have generated unequal access to treatment and an imbalance in distribution of benefits and duties.
Original languageEnglish
Pages (from-to)63-69
Number of pages7
JournalIntellectual Property Forum
Issue number97
Publication statusPublished - 30 Jun 2014
View graph of relations